{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T06:12:35Z","timestamp":1793686355374,"version":"4.5.1"},"reference-count":51,"publisher":"Pleiades Publishing Ltd","issue":"1","license":[{"start":{"date-parts":[[2025,5,11]],"date-time":"2025-05-11T00:00:00Z","timestamp":1746921600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,5,11]],"date-time":"2025-05-11T00:00:00Z","timestamp":1746921600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dokl Biochem Biophys"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1134\/s1607672925700097","type":"journal-article","created":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T10:28:38Z","timestamp":1747045718000},"page":"333-342","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Dynamics of Modified Cardiovascular Risk Factors in Patients with Rheumatoid Arthritis on\u00a0the\u00a0Background of 5-Year Therapy with an Interleukin\u00a06 Receptor Inhibitor"],"prefix":"10.1134","volume":"522","author":[{"given":"E. V.","family":"Gerasimova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T. V.","family":"Popkova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I. G.","family":"Kirillova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. A.","family":"Gerasimova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. L.","family":"Nasonov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"137","published-online":{"date-parts":[[2025,5,11]]},"reference":[{"key":"7689_CR1","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1136\/bmj.k1036","volume":"23","author":"B.R. England","year":"2018","unstructured":"England, B.R., Thiele, G.M., Anderson, D.R., and Mikuls, T.R., Increased cardiovascular risk in rheumatoid arthritis: mechanisms and implications, BMJ, 2018, vol. 23, no. 361, p. 1036.","journal-title":"BMJ"},{"key":"7689_CR2","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.reuma.2017.06.002","volume":"15","author":"A. Balsa","year":"2019","unstructured":"Balsa, A., Lojo-Oliveira, L., Alperi-L\u00f3pez, M., Garc\u00eda-Manrique, M., Ord\u00f3\u00f1ez-Ca\u00f1izares, C., P\u00e9rez, L., et al., Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring in clinical practice: the Spanish cohort of the COMORA study, Reumatol. Clin. (Engl. Ed.), 2019, vol. 15, no. 2, pp. 102\u2013108.","journal-title":"Reumatol. Clin. (Engl. Ed.)"},{"key":"7689_CR3","volume-title":"Revmatologiya: Rossiiskie klinicheskie rekomendatsii (Rheumatology. Russian Clinical Recommendations)","year":"2020","unstructured":"Revmatologiya: Rossiiskie klinicheskie rekomendatsii (Rheumatology. Russian Clinical Recommendations), Nasonov, E.L., Ed., Moscow: GEOTAR-Media, 2020."},{"key":"7689_CR4","doi-asserted-by":"crossref","unstructured":"Baghdadi, L.R., Woodman, R.J., Shanahan, E.M., and Mangoni, A.A., The impact of traditional cardiovascular risk factors on cardiovascular outcomes in patients with rheumatoid arthritis: a systematic review and meta-analysis, PLoS One, 2015, vol. 10, no. 2, p.\u00a0117952.","DOI":"10.1371\/journal.pone.0117952"},{"key":"7689_CR5","doi-asserted-by":"publisher","first-page":"25","DOI":"10.14412\/1996-7012-2013-7","volume":"7","author":"E.V. Udachkina","year":"2013","unstructured":"Udachkina, E.V., Novikova, D.S., Popkova, T.V., and Nasonov, E.L., Role of interleukin-6 in the development of atherosclerosis in rheumatoid arthritis, Modern Rheumatol. J., 2013, vol. 7, no. 3, pp. 25\u201332.","journal-title":"Modern Rheumatol. J."},{"key":"7689_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.atherosclerosis.2018.02.005","volume":"271","author":"A. Eltoft","year":"2018","unstructured":"Eltoft, A., Arntzen, K.A., Wilsgaard, T., Mathiesen, E.B., and Johnsen, S.H., Interleukin-6 is an independent predictor of progressive atherosclerosis in the carotid artery: The Troms\u00f8 Study, Atherosclerosis, 2018, vol.\u00a0271, pp. 1\u20138.","journal-title":"Atherosclerosis"},{"key":"7689_CR7","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1515\/cmble-2015-0020","volume":"20","author":"V. Lubrano","year":"2015","unstructured":"Lubrano, V., Gabriele, M., Puntoni, M.R., Longo, V., and Pucci, L., Relationship among IL-6, LDL cholesterol and lipid peroxidation, Cell Mol. Biol. Lett., 2015, vol. 20, no. 2, pp. 310\u2013322.","journal-title":"Cell Mol. Biol. Lett."},{"key":"7689_CR8","first-page":"768","volume":"56","author":"L.J. Barra","year":"2017","unstructured":"Barra, L.J., Pope, J.E., Hitchon, C., Boire, G., Schieir, O., Lin, D., et al., CATCH group. The effect of rheumatoid arthritis-associated autoantibodies on the incidence of cardiovascular events in a large inception cohort of early inflammatory arthritis, Rheumatology (Oxford), 2017, vol. 56, no. 5, pp. 768\u2013776.","journal-title":"Rheumatology (Oxford)"},{"key":"7689_CR9","first-page":"4","volume":"90","author":"E.L. Nasonov","year":"2018","unstructured":"Nasonov, E.L. and Popkova, T.V., Atherosclerosis: perspectives of anti-inflammatory therapy, Ter. Arkh., 2018, vol. 90, no. 5, pp. 4\u201312.","journal-title":"Ter. Arkh."},{"key":"7689_CR10","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1136\/annrheumdis-2013-204345","volume":"74","author":"I.B. McInnes","year":"2015","unstructured":"McInnes, I.B., Thompson, L., Giles, J.T., Bathon, J.M., Salmon, J.E., Beaulieu, A.D., et al., Effect of interleukin-6 receptor blockade on surrogates of vascular risk in rheumatoid arthritis: MEASURE, a randomised, placebo-controlled study, Ann. Rheum. Dis., 2015, vol. 74, no. 4, pp. 694\u2013702.","journal-title":"Ann. Rheum. Dis."},{"key":"7689_CR11","doi-asserted-by":"crossref","unstructured":"Castagn\u00e9, B., Viprey, M., Martin, K., Schott, A.-M., Cucherat, M., and Soubrier, M., Cardiovascular safety of tocilizumab: a systematic review and network meta-analysis, PLoS One, 2019, vol. 14, no. 8, p. 220178.","DOI":"10.1371\/journal.pone.0220178"},{"key":"7689_CR12","doi-asserted-by":"publisher","first-page":"142","DOI":"10.3899\/jrheum.160287","volume":"44","author":"G. Jones","year":"2017","unstructured":"Jones, G., Wallace, T., McIntosh, M.J., Brockwell, L., G\u00f3mez-Reino, J.J., and Sebba, A., Five-year efficacy and safety of tocilizumab monotherapy in patients with rheumatoid arthritis who were methotrexate- and biologic-naive or free of methotrexate for 6 months: the AMBITION study, J. Rheumatol., 2017, vol. 44, no. 2, pp. 142\u2013146.","journal-title":"J. Rheumatol."},{"key":"7689_CR13","first-page":"590","volume":"55","author":"E.L. Nasonov","year":"2017","unstructured":"Nasonov, E.L. and Lila, A.M., Inhibition of interleukin 6 in immune inflammatory rheumatic diseases: achievements, prospects, and hopes, Nauchno-Prakt. Revmatol., 2017, vol. 55, no. 6, pp. 590\u2013599.","journal-title":"Nauchno-Prakt. Revmatol."},{"key":"7689_CR14","first-page":"46","volume":"10","author":"Committee of Experts RCS","year":"2011","unstructured":"Committee of Experts RCS. National recommendations for cardiovascular prophylaxis, Cardiovasc. Ther. Prevention, 2011, vol. 10, no. 6 (suppl. 2), p. 46.","journal-title":"Cardiovasc. Ther. Prevention"},{"key":"7689_CR15","first-page":"84","volume":"59","author":"E.V. Gerasimova","year":"2021","unstructured":"Gerasimova, E.V., Popkova, T.V., Martynova, A.V., Kirillova, I.G., Markelova, E.I., Semashko, A.S., et al., Dynamics of traditional modifiable risk factors, total cardiovascular risk, and structural changes of carotid arteries in patients with rheumatoid arthritis on long-term interleukin-6 receptor antagonist treatment, Nauchno-Prakt. Revmatol., 2021, vol. 59, no. 1, pp. 84\u201392.","journal-title":"Nauchno-Prakt. Revmatol."},{"key":"7689_CR16","first-page":"9","volume":"84","author":"T.V. Popkova","year":"2012","unstructured":"Popkova, T.V., Novikova, D.S., Panasyuk, E.Y., Avdeeva, A.S., Udachkina, E.V., Alexandrova, E.N., et al., Tocilizumab impact on blood cholesterine transport and early manifestation of atherosclerosis in patients with rheumatoid arthritis, Ter. Arkh., 2012, vol. 84, no.\u00a05, pp. 9\u201318.","journal-title":"Ter. Arkh."},{"key":"7689_CR17","doi-asserted-by":"publisher","first-page":"1806","DOI":"10.1136\/annrheumdis-2015-207872","volume":"75","author":"C. Gabay","year":"2016","unstructured":"Gabay, C., McInnes, I.B., Kavanaugh, A., Tuckwell, K., Klearman, M., Pulley, J., et al., Comparison of lipid and lipid-associated cardiovascular risk marker changes after treatment with tocilizumab or adalimumab in patients with rheumatoid arthritis, Ann. Rheum. Dis., 2016, vol. 75, no. 10, pp. 1806\u20131812.","journal-title":"Ann. Rheum. Dis."},{"key":"7689_CR18","doi-asserted-by":"publisher","first-page":"107","DOI":"10.3390\/metabo10030107","volume":"10","author":"E. Toussirot","year":"2020","unstructured":"Toussirot, E., The interrelations between biological and targeted synthetic agents used in inflammatory joint diseases, and obesity or body composition, Metabolites, 2020, vol. 10, no. 3, p. 107.","journal-title":"Metabolites"},{"key":"7689_CR19","doi-asserted-by":"crossref","unstructured":"Choi, I., Sagawa, A., Lee, E., Lee, E.B., and Song, Y.W., Tocilizumab increases body weight and serum adipokine levels in patients with rheumatoid arthritis independently of their treatment response: a retrospective cohort study, J. Korean Med. Sci., 2020, vol. 35, no. 22, p. e55.","DOI":"10.3346\/jkms.2020.35.e155"},{"key":"7689_CR20","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1002\/jcsm.12189","volume":"8","author":"A. Tournadre","year":"2017","unstructured":"Tournadre, A., Pereira, B., Dutheil, F., Giraud, C., Courteix, D., Sapin, V., et al., Changes in body composition and metabolic profile during interleukin 6 inhibition in rheumatoid arthritis, J. Cachexia Sarcopenia Muscle, 2017, vol. 8, no. 4, pp. 639\u2013646.","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"7689_CR21","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s13395-017-0140-z","volume":"7","author":"E. Wada","year":"2017","unstructured":"Wada, E., Tanihata, J., Iwamura, A., Takeda, S., Hayashi, Y.K., and Matsuda, R., Treatment with the anti-IL-6 receptor antibody attenuates muscular dystrophy via promoting skeletal muscle regeneration in dystrophin-\/utrophin-deficient mice, Skeletal Muscle, 2017, vol. 7, no. 1, p. 23.","journal-title":"Skeletal Muscle"},{"key":"7689_CR22","doi-asserted-by":"crossref","unstructured":"Ando, K., Takahashi, F., Kato, M., Kaneko, N., Doi, T., Ohe, Y., et al., Tocilizumab, a proposed therapy for the cachexia of Interleukin6-expressing lung cancer, PLoS One, 2014, vol. 9, no. 7, p. e102436.","DOI":"10.1371\/journal.pone.0102436"},{"key":"7689_CR23","doi-asserted-by":"publisher","first-page":"2968","DOI":"10.1002\/art.23940","volume":"58","author":"M.C. Genovese","year":"2008","unstructured":"Genovese, M.C., McKay, J.D., Nasonov, E.L., Mysler, E.F., da Silva, N.A., Alecock, E., et al., Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study, Arthritis Rheum., 2008, vol. 58, no. 10, pp. 2968\u20132980.","journal-title":"Arthritis Rheum."},{"key":"7689_CR24","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1007\/s40744-016-0049-8","volume":"4","author":"M. Soubrier","year":"2017","unstructured":"Soubrier, M., Pei, J., Durand, F., Gullestad, L., and John A., Concomitant use of statins in tocilizumab-treated patients with rheumatoid arthritis: a post hoc analysis, Rheumatol. Ther., 2017, vol. 4, no. 1, pp. 133\u2013149.","journal-title":"Rheumatol. Ther."},{"key":"7689_CR25","doi-asserted-by":"publisher","first-page":"4633","DOI":"10.3390\/ijms20184633","volume":"20","author":"E. Hoffman","year":"2019","unstructured":"Hoffman, E., Rahat, M.A., Feld, J., Elias, M., Rosner, I., Kaly, L., et al., Effects of tocilizumab, an anti-interleukin-6 receptor antibody, on serum lipid and adipokine levels in patients with rheumatoid arthritis, Int. J. Mol. Sci., 2019, vol. 20, no. 18, p. 4633.","journal-title":"Int. J. Mol. Sci."},{"key":"7689_CR26","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/ar3455","volume":"13","author":"M.H. Schiff","year":"2011","unstructured":"Schiff, M.H., Kremer, J.M., Jahreis, A., Vernon, E., Isaacs, J.D., and van Vollenhoven, R.F., Integrated safety in tocilizumab clinical trials, Arthritis Res. Ther., 2011, vol. 13, p. 141.","journal-title":"Arthritis Res. Ther."},{"key":"7689_CR27","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1016\/S0140-6736(11)61931-4","volume":"379","author":"N. Sarwar","year":"2012","unstructured":"Sarwar, N., Butterworth, A.S., Freitag, D.F., Gregson, J., Willeit, P., Gorman, D.N., et al., R Genetics Consortium Emerging Risk Factors Collaboration, Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies, Lancet, 2012, vol. 379, no. 9822, pp. 1205\u20131213.","journal-title":"Lancet"},{"key":"7689_CR28","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/j.semarthrit.2013.08.001","volume":"43","author":"G. Navarro","year":"2014","unstructured":"Navarro, G., Taroumian, S., Barroso, N., Duan, L., and Furs, D., Tocilizumab in rheumatoid arthritis: a meta-analysis of efficacy and selected clinical conundrums, Semin. Arthritis Rheum., 2014, vol. 43, no. 4, pp.\u00a0458\u2013469.","journal-title":"Semin. Arthritis Rheum."},{"key":"7689_CR29","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1002\/art.40892","volume":"71","author":"G.D. Kitas","year":"2019","unstructured":"Kitas, G.D., Nightingale, P., Armitage, J., Sattar, N., Belch, J.J.F., and Symmons, D.P., A multicenter, randomized, placebo-controlled trial of atorvastatin for the primary prevention of cardiovascular events in patients with rheumatoid arthritis, Arthritis Rheumatol., 2019, vol. 71, no. 9, pp. 1437\u20131449.","journal-title":"Arthritis Rheumatol."},{"key":"7689_CR30","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1002\/art.21521","volume":"54","author":"A.M. Abeles","year":"2006","unstructured":"Abeles, A.M. and Pillinge, M.H., Statins as antiinflammatory and immunomodulatory agents: a future in rheumatologic therapy?, Arthritis Rheumatol., 2006, vol. 54, no. 2, pp. 393\u2013407.","journal-title":"Arthritis Rheumatol."},{"key":"7689_CR31","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1007\/s12265-020-09964-9","volume":"13","author":"J. Halacoglu","year":"2020","unstructured":"Halacoglu, J. and Shea, L.A., Cardiovascular risk assessment and therapeutic implications in rheumatoid arthritis, J. Cardiovasc. Transl. Res., 2020, vol. 13, pp.\u00a0878\u2013890.","journal-title":"J. Cardiovasc. Transl. Res."},{"key":"7689_CR32","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.smim.2014.01.009","volume":"26","author":"T. Tanaka","year":"2014","unstructured":"Tanaka, T., Narazaki, M., Ogata, A., and Kishimoto, T., A new era for the treatment of inflammatory autoimmune diseases by interleukin-6 blockade strategy, Semin. Immunol., 2014, vol. 26, no. 1, pp. 88\u201396.","journal-title":"Semin. Immunol."},{"key":"7689_CR33","doi-asserted-by":"crossref","unstructured":"Cacciapaglia, F., Anelli, M.G., Rinaldi, A., Fornaro, M., Lopalco, G., Scioscia, C., et al., Lipids and atherogenic indices fluctuation in rheumatoid arthritis patients on long-term tocilizumab treatment, Mediators Inflamm., 2018, vol. 2018, p. 2453265.","DOI":"10.1155\/2018\/2453265"},{"key":"7689_CR34","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1002\/art.40084","volume":"69","author":"S.C. Kim","year":"2017","unstructured":"Kim, S.C., Solomon, D.H., Rogers, J.R., Gale, S., Klearman, M., Sarsour, K., et al., Cardiovascular safety of tocilizumab versus tumor necrosis factor inhibitors in patients with rheumatoid arthritis: a multi-database cohort study, Arthritis Rheumatol., 2017, vol. 69, no. 6, pp. 1154\u20131164.","journal-title":"Arthritis Rheumatol."},{"key":"7689_CR35","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1055\/a-0833-4627","volume":"51","author":"I. Ferraz-Amaro","year":"2019","unstructured":"Ferraz-Amaro, I., Hern\u00e1ndez-Hern\u00e1ndez, M.V., Tejera-Segura, B., Delgado-Fr\u00edas, E., Mac\u00eda-D\u00edaz, M., Machado, J.D., et al., Effect of IL-6 receptor blockade on proprotein convertase subtilisin\/kexin type-9 and cholesterol efflux capacity in rheumatoid arthritis patients, Horm. Metab. Res., 2019, vol. 51, no. 3, pp. 200\u2013209.","journal-title":"Horm. Metab. Res."},{"key":"7689_CR36","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.atherosclerosis.2013.04.031","volume":"229","author":"A.C. Strang","year":"2013","unstructured":"Strang, A.C., Bisoendial, R.J., Kootte, R.S., Schulte,\u00a0\u00a0D.M., Dallinga-Thie, G.M., Levels, J.H., et\u00a0al., Pro-atherogenic lipid changes and decreased hepatic LDL receptor expression by tocilizumab in rheumatoid arthritis, Atherosclerosis, 2013, vol. 229, no. 1, pp. 174\u2013181.","journal-title":"Atherosclerosis"},{"key":"7689_CR37","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.trsl.2016.12.003","volume":"183","author":"P. Ruiz-Lim\u00f3n","year":"2017","unstructured":"Ruiz-Lim\u00f3n, P., Ortega, R., Arias de la Rosa, I., Abalos-Aguilera, M.D.C., Perez-Sanchez, C., Jimenez-Gomez, Y., et al., Tocilizumab improves the proatherothrombotic profile of rheumatoid arthritis patients modulating endothelial dysfunction, NETosis, and inflammation, Transl. Res., 2017, vol. 183, pp. 87\u2013103.","journal-title":"Transl. Res."},{"key":"7689_CR38","doi-asserted-by":"crossref","unstructured":"Bacchiega, B.C., Bacchiega, A.B., Usnayo, M., Bedirian, R., Singh, G., and Pinheiro, G., Interleukin 6 inhibition and coronary artery disease in a high-risk population: a prospective community-based clinical study, J. Am. Heart Assoc., 2017, vol. 6, no. 3, p. e005038.","DOI":"10.1161\/JAHA.116.005038"},{"key":"7689_CR39","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1007\/s00392-019-01443-9","volume":"108","author":"I. Ikonomidis","year":"2019","unstructured":"Ikonomidis, I., Pavlidis, G., Katsimbri, P., Andreadou, I., Triantafyllidi, H., and Tsoumani, M., Differential effects of inhibition of interleukin 1 and 6 on myocardial, coronary and vascular function, Clin. Res. Cardiol., 2019, vol. 108, no. 10, pp. 1093\u20131101.","journal-title":"Clin. Res. Cardiol."},{"key":"7689_CR40","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.3899\/jrheum.110340","volume":"38","author":"K. Kume","year":"2011","unstructured":"Kume, K., Amano, K., Yamada, S., Hatta, K., Ohta, H., and Kuwaba, N., Tocilizumab monotherapy reduces arterial stiffness as effectively as etanercept or adalimumab monotherapy in rheumatoid arthritis: an open-label randomized controlled trial, J. Rheumatol., 2011, vol. 38, no. 10, pp. 2169\u20132171.","journal-title":"J. Rheumatol."},{"key":"7689_CR41","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s13075-015-0559-8","volume":"17","author":"D.Y. Chen","year":"2015","unstructured":"Chen, D.Y., Chen, Y.M., Hsieh, T.Y., Hsieh, C.W., Lin, C.C., and Lan, J.L., Significant effects of biologic therapy on lipid profiles and insulin resistance in patients with rheumatoid arthritis, Arthritis Res. Ther., 2015, vol. 17, no. 1, p. 52.","journal-title":"Arthritis Res. Ther."},{"key":"7689_CR42","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1002\/art.38920","volume":"67","author":"V.U. Rao","year":"2015","unstructured":"Rao, V.U., Pavlov, A., Klearman, M., Musselman, D., Giles, J.T., Bathon, J.M., et al., An evaluation of risk factors for major adverse cardiovascular events during tocilizumab therapy, Arthritis Rheumatol., 2015, vol. 67, no. 2, pp. 372\u2013380.","journal-title":"Arthritis Rheumatol."},{"key":"7689_CR43","doi-asserted-by":"publisher","first-page":"2924","DOI":"10.1161\/STROKEAHA.114.005991","volume":"45","author":"S. Okazaki","year":"2014","unstructured":"Okazaki, S., Sakaguchi, M., Miwa, K., Furukado, S., Yamagami, H., and Yagita, Y., Association of interleukin-6 with the progression of carotid atherosclerosis: a 9-year follow-up study, Stroke, 2014, vol. 45, no. 10, pp.\u00a02924\u20132929.","journal-title":"Stroke"},{"key":"7689_CR44","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.atherosclerosis.2017.06.008","volume":"263","author":"P. Puz","year":"2017","unstructured":"Puz, P. and Lasek-Bal, A., Repeated measurements of serum concentrations of TNF-alpha, interleukin-6 and interleukin-10 in the evaluation of internal carotid artery stenosis progression, Atherosclerosis, 2017, vol. 263, pp. 97\u2013103.","journal-title":"Atherosclerosis"},{"key":"7689_CR45","doi-asserted-by":"publisher","first-page":"189","DOI":"10.3390\/diagnostics9040189","volume":"9","author":"N. Pauli","year":"2019","unstructured":"Pauli, N., Pucha\u0142owicz, K., Kuligowska, A., Krzystolik, A., Dziedziejko, V., Safranow, K., et al., Associations between IL-6 and echo-parameters in patients with early onset coronary artery disease, Diagnostics (Basel), 2019, vol. 9, no. 4, p. 189.","journal-title":"Diagnostics (Basel)"},{"key":"7689_CR46","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1136\/annrheumdis-2015-207870","volume":"75","author":"J. Zhang","year":"2016","unstructured":"Zhang, J., Xie, F., Yun, H., Chen, L., Muntner, P., and Levitan, E.B., Comparative effects of biologics on cardiovascular risk among older patients with rheumatoid arthritis, Ann. Rheum. Dis., 2016, vol. 75, no. 10, pp.\u00a01813\u20131818.","journal-title":"Ann. Rheum. Dis."},{"key":"7689_CR47","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1093\/rheumatology\/keu101.023","volume":"53","author":"S. Grange","year":"2014","unstructured":"Grange, S., Schmitt, C., Ganeshalingam, K., and Choy, E.H., Tocilizumab did not significantly increase serum cholesterol levels in healthy subjects, Rheumatology, 2014, vol. 53, pp. 95\u201396.","journal-title":"Rheumatology"},{"key":"7689_CR48","first-page":"1657","volume":"40","author":"C. Specker","year":"2022","unstructured":"Specker, C., Aringer, M., Burmester, G.R., Killy, B., Hofmann, M.W., and Kellner, H., The safety and effectiveness of tocilizumab in elderly patients with rheumatoid arthritis and in patients with comorbidities associated with age, Clin. Exp. Rheumatol., 2022, vol. 40, no. 9, pp. 1657\u20131665.","journal-title":"Clin. Exp. Rheumatol."},{"key":"7689_CR49","doi-asserted-by":"publisher","first-page":"319","DOI":"10.55563\/clinexprheumatol\/3qdgi1","volume":"39","author":"C. Specker","year":"2021","unstructured":"Specker, C., Alberding, A., Aringer, M., Burmester,\u00a0\u00a0\u00a0\u00a0G.R., Flacke, J.P., Hofmann, M.W., et al., ICHIBAN, a non-interventional study evaluating tocilizumab long-term effectiveness and safety in patients with active rheumatoid arthritis, Clin. Exp. Rheumatol., 2021, vol. 39, no. 2, pp. 319\u2013328.","journal-title":"Clin. Exp. Rheumatol."},{"key":"7689_CR50","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1177\/1759720x18798462","volume":"10","author":"G. Jones","year":"2018","unstructured":"Jones, G. and Panova, E., New insights and long-term safety of tocilizumab in rheumatoid arthritis, Ther. Adv. Musculoskeletal Dis., 2018, vol. 10, no. 10, pp. 195\u2013199. https:\/\/doi.org\/10.1177\/1759720x18798462","journal-title":"Ther. Adv. Musculoskeletal Dis."},{"key":"7689_CR51","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/s40744-019-0139-5","volume":"6","author":"S. Gale","year":"2019","unstructured":"Gale, S., Trinh, H., Tuckwell, K., Collinson, N., Stone, J.H., Sarsour, K., et al., Adverse events in giant cell arteritis and rheumatoid arthritis patient populations: analyses of tocilizumab clinical trials and claims data, Rheumatol. Ther., 2019, vol. 6, no. 1, pp. 77\u201388.","journal-title":"Rheumatol. Ther."}],"container-title":["Doklady Biochemistry and Biophysics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1134\/S1607672925700097.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1134\/S1607672925700097","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1134\/S1607672925700097.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T15:18:01Z","timestamp":1773760681000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1134\/S1607672925700097"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,11]]},"references-count":51,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["7689"],"URL":"https:\/\/doi.org\/10.1134\/s1607672925700097","relation":{},"ISSN":["1607-6729","1608-3091"],"issn-type":[{"value":"1607-6729","type":"print"},{"value":"1608-3091","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,11]]},"assertion":[{"value":"2 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 February 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 February 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the local ethics committee of Nasonova Research Institute of Rheumatology (protocol no. 2 dated September 2, 2022). All patients signed informed consent to participate in the study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"ETHICS APPROVAL AND CONSENT TO PARTICIPATE"}},{"value":"The authors of this work declare that they have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"CONFLICT OF INTEREST"}}]}}